These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17146377)

  • 1. Effects on asymmetric dimethylarginine of HMR 3339, a novel selective estrogen receptor modulator: a 12-week, randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.
    Verhoeven MO; Teerlink T; Kenemans P; Vogelvang TE; van der Mooren MJ;
    Menopause; 2007; 14(2):235-42. PubMed ID: 17146377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women.
    Vogelvang TE; Mijatovic V; Kenemans P; Teerlink T; van der Mooren MJ
    Fertil Steril; 2004 Dec; 82(6):1540-9. PubMed ID: 15589857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.
    Vogelvang TE; Mijatovic V; Kenemans P; Emeis JJ; Heijst JA; van der Mooren MJ
    Am J Obstet Gynecol; 2005 Oct; 193(4):1384-94. PubMed ID: 16202731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women.
    Vogelvang TE; Mijatovic V; Kenemans P; Schalkwijk CG; van der Mooren MJ
    Am J Cardiol; 2004 Nov; 94(9):1205-8. PubMed ID: 15518626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study.
    Verhoeven MO; Hemelaar M; van der Mooren MJ; Kenemans P; Teerlink T
    J Intern Med; 2006 Feb; 259(2):199-208. PubMed ID: 16420549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women.
    Teerlink T; Neele SJ; de Jong S; Netelenbos JC; Stehouwer CD
    Clin Sci (Lond); 2003 Jul; 105(1):67-71. PubMed ID: 12625833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: a randomized study.
    Verhoeven MO; Hemelaar M; Teerlink T; Kenemans P; van der Mooren MJ
    Atherosclerosis; 2007 Nov; 195(1):181-8. PubMed ID: 17084844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
    Aldrighi JM; Quail DC; Levy-Frebault J; Aguas F; Kosian K; Garrido L; Bosio-Le Goux B; Saráchaga M; Graebe A; Niño AJ; Nickelsen T
    Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.
    Stovall DW; Utian WH; Gass ML; Qu Y; Muram D; Wong M; Plouffe L
    Menopause; 2007; 14(3 Pt 1):510-7. PubMed ID: 17314736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of raloxifene and low-dose percutaneous 17beta-estradiol on menopause symptoms and endometrium--a randomized controlled trial.
    Valiati B; Capp E; Edelweiss MI; de Freitas FM; Wender MC
    Maturitas; 2009 Jan; 62(1):81-4. PubMed ID: 19097715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.
    Usall J; Huerta-Ramos E; Iniesta R; Cobo J; Araya S; Roca M; Serrano-Blanco A; Teba F; Ochoa S
    J Clin Psychiatry; 2011 Nov; 72(11):1552-7. PubMed ID: 21903021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate.
    Palacios S; Farias ML; Luebbert H; Gomez G; Yabur JA; Quail DC; Turbi C; Kayath MJ; Almeida MJ; Mönnig E; Nickelsen T
    Am J Obstet Gynecol; 2004 Jul; 191(1):121-31. PubMed ID: 15295352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
    Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raloxifene improves verbal memory in late postmenopausal women: a randomized, double-blind, placebo-controlled trial.
    Jacobsen DE; Samson MM; Emmelot-Vonk MH; Verhaar HJ
    Menopause; 2010 Mar; 17(2):309-14. PubMed ID: 19918203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
    Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L
    Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia.
    Kulkarni J; Gurvich C; Lee SJ; Gilbert H; Gavrilidis E; de Castella A; Berk M; Dodd S; Fitzgerald PB; Davis SR
    Psychoneuroendocrinology; 2010 Sep; 35(8):1142-7. PubMed ID: 20171784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women.
    Post MS; Verhoeven MO; van der Mooren MJ; Kenemans P; Stehouwer CD; Teerlink T
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4221-6. PubMed ID: 12970290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].
    Zhou YZ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Lin SQ
    Zhonghua Fu Chan Ke Za Zhi; 2011 May; 46(5):345-9. PubMed ID: 21733370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients.
    Dowsett M; Bundred NJ; Decensi A; Sainsbury RC; Lu Y; Hills MJ; Cohen FJ; Veronesi P; O'Brien ME; Scott T; Muchmore DB
    Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):961-6. PubMed ID: 11535548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study.
    O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Wolthers T; Davis SR
    Climacteric; 2003 Dec; 6(4):347-53. PubMed ID: 15006256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.